Anthony R. Mato, Jakub Svoboda, Tatyana Feldman, Tania Zielonka, Harry Agress, David Panush, Mitchell Miller, Patrick Toth, Paul M. Lizotte, Sunita Nasta, Stuart Goldberg, Emeline Chong, Steven Schuster, Andrew L. Pecora and Andre Goy Post-treatment (not interim) positron emission tomography-computed tomography scan status is highly predictive of outcome in mantle cell lymphoma patients treated with R-HyperCVAD Cancer 118
Version of Record online: 16 DEC 2011 | DOI: 10.1002/cncr.26731
Positron emission tomography (PET)-computed tomography (CT) performed after the completion of dose-intensive immunochemotherapy is an independent predictor of progression-free survival (PFS) with a trend toward predicting overall survival (OS) in mantle cell lymphoma patients. Performing a midtreatment (interim) PET-CT in this patient population does not have prognostic utility for PFS or OS and therefore is not clinically indicated.
Complete the form below and we will send an e-mail message containing a link to the selected article on your behalf
Required = Required Field